Paul Richardson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses his highlights of the 20th Congress of the European Hematology Association (EHA). A substantial number of new agents, including monoclonal antibodies, and emerging drug classes in clinical development have shown promising activity for the treatment of multiple myeloma.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates